From Financial Modeling Prep: 2025-04-25 09:23:00

Gilead Sciences (NASDAQ:GILD) reported strong first-quarter earnings but saw a more than 3% drop in share price due to revenue shortfall and poor oncology division performance. Adjusted earnings were $1.81 per share, beating expectations, but revenue of $6.67 billion fell short of the $6.78 billion estimate.

HIV therapies, Gilead’s primary revenue driver, saw 6% year-over-year growth to $4.6 billion, with flagship drug Biktarvy rising 7% to $3.1 billion. However, total HIV sales were down 16% from the previous quarter due to seasonal patterns and inventory dynamics.

The company’s oncology segment struggled, with key cancer treatment Trodelvy generating $293 million, below expectations of $362 million. Cell therapy revenue also declined 3% to $464 million, impacted by increased competition in the U.S. market.

Despite the revenue miss, Gilead maintained its full-year 2025 guidance, projecting adjusted EPS between $7.70 and $8.10 and revenue in the range of $28.2 billion to $28.6 billion. However, the revenue target is slightly below analyst forecasts, leading to investor caution.



Read more at Financial Modeling Prep:: Gilead Beats on Earnings but Weak Oncology Sales D…